New research reveals that people who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy may regain shed pounds much more quickly than those who halt conventional diet and exercise programs.
Research printed in a leading health publication demonstrates that while overweight people can lose substantial amounts of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"Individuals purchasing such drugs need to be aware of the risk of rapid weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass in about one and a half years.
Comparing Treatments
The analysis, which looked at dozens of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists note that people who lose weight through diet and exercise usually experience a slower creep back—around 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Doctors believe the mode of action of the drugs explains the amplified rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone levels several times higher than normal might result in the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the significant potential of relapse, the therapy should be considered ongoing.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," similar to managing conditions like diabetes.
Patient Experiences
People who have discontinued the medication describe a powerful return of hunger.
"I experienced a trigger flipping and I was suddenly starving," said a patient.
This challenge is compounded if patients have not adopted permanent dietary or behavioural changes during therapy.
Growing Interest
Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is more common among women than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, experts stress that while the jabs are potent tools for weight loss, they are not a standalone fix and lasting health benefits likely depends on ongoing behavioural support.
